NIH Reporter #75N95022D00021-0-759502300001-1

ELISA Assay Development for NIH Blueprint Neurotherapeutics Biologics Project

This opportunity involves the National Institute on Drug Abuse (NIDA) and the National Institute of Neurological Disorders and Stroke (NINDS) procuring specialized assay development services for neurological research. - Government Buyer: - National Institute on Drug Abuse (NIDA) - National Institute of Neurological Disorders and Stroke (NINDS) - OEMs and Vendors: - Example Biotech Inc. (mentioned as a bidder) - Products/Services Requested: - Development of Enzyme-Linked Immunosorbent Assays (ELISAs) - Focus on treatments for neurological disorders, specifically Duchenne's muscular dystrophy and antibody therapy development - One lot of ELISA assay development - Unique/Notable Requirements: - Project is part of the NIH Blueprint Neurotherapeutics (BPN) Biologics Project - Work to be performed in Columbus, Ohio - Falls under NAICS code 541710 (Research and Development in Biotechnology) and PSC code 6550 (Medical and Surgical Instruments, Equipment, and Supplies) - Cooperative agreement structure - No specific OEMs or part numbers provided - Estimated contract value: $394,434

Description

This project involves the development of ELISA assays for neurological disorder treatments, specifically targeting Duchenne's muscular dystrophy, with a focus on antibody therapy development. The work is conducted under a cooperative agreement funded by the National Institute of Neurological Disorders and Stroke (NINDS) and managed by the National Institute on Drug Abuse (NIDA). The project duration is from February 7, 2023, to February 6, 2028, with an estimated value of $394,434. The location for the work is Columbus, Ohio, United States.

View original listing